Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio

Centivax完成由Future Ventures领投的4500万美元超额认购A轮融资，推动通用流感疫苗进入临床并扩展通用免疫产品组合。

• Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Partners, Base4 Capital and others

• 超额认购轮融资由Future Ventures领投，NFX、BOLD Capital Partners、Kendall Capital Partners、Amplify Partners、Base4 Capital等参与。

• Dr. Emilio Emini, former SVP of Vaccine Research and Development at Pfizer, SVP of Research at Merck, and CEO of the Bill & Melinda Gates Medical Research Institute, joins the Board of Directors

• 辉瑞疫苗研发前高级副总裁、默克研究部门前高级副总裁、比尔及梅琳达·盖茨医学研究所前首席执行官埃米利奥·埃米尼博士加入董事会。

SOUTH SAN FRANCISCO, Calif., July 8, 2025-- Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed $45 million Series A financing. The round was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, SpaceX, Prellis Biologics, Cambrian Bio, and others which in aggregate represent $1.4 trillion of value creation.

南旧金山，加利福尼亚州，2025年7月8日——Centivax, Inc.是一家致力于开发针对高度多样化病原体的持久性、通用性疫苗和疗法的生物技术公司，今天宣布完成了超额认购的4500万美元A轮融资。本轮融资由Future Ventures的史蒂夫·尤尔韦特森（Steve Jurvetson）领投，他是特斯拉、SpaceX、Prellis Biologics、Cambrian Bio等公司的早期支持者，这些公司总共创造了1.4万亿美元的价值。

The round includes participation from NFX, BOLD Capital Partners, Base4 Capital, Kendall Capital Partners, Amplify Partners, and other investors. Existing insiders increased their ownership in the round..

本轮融资包括NFX、BOLD Capital Partners、Base4 Capital、Kendall Capital Partners、Amplify Partners和其他投资者的参与。现有内部人士在本轮增加了他们的持股比例。

'Future Ventures is proud to lead Centivax's Series A with a great syndicate of co-investors,' said lead investor Steve Jurvetson. 'I have been on a quest to find a credible antiviral breakthrough for over 20 years. I first became enamored with the prospect of a universal vaccine via our philanthropy.

“未来风险投资公司很荣幸能够与一群优秀的共同投资者一起主导Centivax的A轮融资，”首席投资者史蒂夫·尤尔韦特森表示。“二十多年来，我一直在寻找一种可信的抗病毒突破。我首先通过我们的慈善事业对通用疫苗的前景产生了浓厚的兴趣。

Centivax has developed a universal shot for all forms of flu, and they have already demonstrated their universal immunity platforms in other areas, including universal antivenom. Their unique approach will hopefully lead to a historic transition to a post-pandemic era for humanity.'.

Centivax已经开发出一种适用于所有流感形式的通用疫苗，并且他们已经在其他领域展示了其通用免疫平台，包括通用抗蛇毒血清。他们独特的方法有望引领人类进入后疫情时代的历史性过渡。

The Series A will fund Centivax's first clinical candidate, a universal flu vaccine currently in CMC development, through a Phase I clinical trial slated to begin within eight months. In addition to safety, the study will measure correlate-of-protection efficacy using the gold-standard hemagglutination inhibition (HAI) assay against a panel of more than twenty flu strains—including current 2024-2025 circulating strains, historical mismatch strains, and pandemic strains—in a direct head-to-head comparison with existing standard-of-care flu vaccines.

A轮融资将为Centivax的第一个临床候选产品——一种目前正在进行CMC开发的通用流感疫苗——提供资金，用于计划在八个月内启动的I期临床试验。除了安全性评估外，该研究还将使用金标准的血凝抑制（HAI）试验，针对二十多种流感毒株——包括当前2024-2025年流行毒株、历史错配毒株和大流行毒株——进行保护相关性功效测量，并与现有的标准护理流感疫苗进行直接对比。

Because the HAI assay is the same correlate-of-protection used to license seasonal flu vaccines, positive data will provide a clear benchmark demonstrating the candidate's ability to deliver broad protection with a single vaccine. 'The Phase I trial gives us the opportunity to prove the Centivax platform technology works,' said Dr.

由于HAI检测是用于批准季节性流感疫苗的相同保护相关指标，积极的数据将提供一个明确的基准，证明候选疫苗能够通过单一疫苗提供广泛的保护。 “一期试验让我们有机会证明Centivax平台技术的有效性，”博士说道。

Jerald Sadoff, MD, Chief Medical Officer of Centivax. 'We can demonstrate that the Centivax technology directs the immune system to focus on regions of pathogens that do not change across strains. This is valuable not just in flu, but for all rapidly mutating pathogens and other difficult targets in our portfolio.' In preclinical studies in ferrets, pigs, cows, mice, rats, and human immune organoids, the Centivax technology consistently induced universal immunity to all tested influenza viruses, including the 2024-2025 H5N1 'bird flu.'.

杰拉尔德·萨多夫（Jerald Sadoff）医学博士，Centivax首席医疗官表示：“我们可以证明，Centivax技术能够引导免疫系统集中攻击病原体中在不同毒株间不会变化的区域。这不仅对流感有价值，还适用于所有快速变异的病原体以及我们产品组合中的其他难以应对的目标。”在雪貂、猪、牛、小鼠、大鼠和人类免疫类器官的临床前研究中，Centivax技术始终诱导出对所有测试流感病毒的广泛免疫，包括2024-2025年的H5N1“禽流感”。

Beyond its flagship universal-flu program, Centivax's epitope-focusing platform enables a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom that was recently published in Cell and spotlighted by the Wall Street Journal, New York Times, Nature, and other outlets.

除了其旗舰的通用流感项目外，Centivax的表位聚焦平台还推动了针对RSV/hMPV、疱疹病毒、HIV、疟疾、肿瘤学以及一种最近在《细胞》杂志上发表并受到《华尔街日报》、《纽约时报》、《自然》及其他媒体报道的通用抗蛇毒血清等越来越多的项目管线。

This growing portfolio underscores the technology's broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease.

这一不断增长的产品组合突显了该技术的广泛潜力，不仅能够防范包括病毒、细菌、原虫、真菌、寄生虫以及人为生物恐怖威胁在内的多种传染病，还能够通过减少这些病原体可能引发的长期并发症（如癌症、自身免疫疾病、心血管和神经退行性疾病）来延长健康寿命。

'Vaccines are already doing this. The Gardasil® vaccine, which our CMO played a key role in developing, reduced the national incidence of multiple cancer types, and was, in effect, an anti-cancer vaccine,' said Dr. Jacob Glanville, PhD, co-founder and CEO of Centivax, 'The Zostavax™ vaccine, which our CMO also spearheaded, has been recently demonstrated to reduce Alzheimer's and heart disease.

“疫苗已经在这样做了。我们的首席医学官在开发Gardasil®疫苗中发挥了关键作用，该疫苗降低了多种癌症的全国发病率，实际上是一种抗癌疫苗，” Centivax的联合创始人兼首席执行官Jacob Glanville博士说道，“我们的首席医学官也主导了Zostavax™疫苗的研发，最近被证明可以减少阿尔茨海默病和心脏病。”

We believe that universal vaccines can take us further.'.

我们相信通用疫苗可以让我们走得更远。

Centivax is led by CEO and founder Dr. Jacob Glanville, former founder and CEO of Distributed Bio, whose clients included Pfizer, Boehringer, Gilead, Teva, and 60 other biotechs and pharmaceutical companies and was acquired by Charles River Laboratories in 2020; Chief Medical Officer Dr. Jerald Sadoff, who previously led vaccine development at Johnson & Johnson, Merck, WRAIR, and AERAS, resulting in 14 vaccines receiving regulatory approval, including Gardasil®, Zostavax™, ProQuad®, Rotateq®, and the Janssen Jcovden COVID-19 vaccine; Chief Scientific Officer and co-founder Dr.

Centivax由首席执行官兼创始人杰克·格兰维尔博士领导，他曾是Distributed Bio的创始人和首席执行官，该公司客户包括辉瑞、勃林格殷格翰、吉利德、梯瓦等60多家生物技术和制药公司，并于2020年被查尔斯河实验室收购；首席医学官杰拉尔德·萨多夫博士，曾领导强生、默克、WRAIR和AERAS的疫苗开发，促成了14种疫苗获得监管批准，包括佳达修®、欣泽特™、普罗奎德®、轮达净®和杨森Jcovden新冠疫苗；首席科学官兼联合创始人博士。

Sawsan Youssef, who successfully exited Distributed Bio with Glanville in 2020, and whose work at Pfizer led to the clinical-stage drug sasanlimab; and co-founder and Chief Business Officer Stephanie Wisner, MBA, formerly of ARCH Venture Partners and author of Building Backwards to Biotech. The leadership team also includes Chief Innovation Officer Dr.

桑丝·尤瑟夫曾于2020年与格兰维尔成功退出分布式生物公司，其在辉瑞的工作促成了临床阶段药物萨桑利单抗；联合创始人兼首席商务官史蒂芬妮·威斯纳，工商管理硕士，曾就职于ARCH风险投资公司，并著有《逆向构建生物科技》。领导团队还包括首席创新官博士。

Gusti Zeiner, Chief Operations Officer and co-founder David Tsao, and Chief Technology Officer and co-founder Dr. Nicholas Bayless..

古斯蒂·泽纳，首席运营官兼联合创始人蔡大卫，以及首席技术官兼联合创始人尼古拉斯·贝勒斯博士。

'Universal vaccines won't just be safer, more reliable, and more convenient medicine—their commercialization will end the pandemic era,' said Glanville. 'I am particularly excited to partner with Steve Jurvetson at Future Ventures due to his track record of new industry formation based on disruptive technology.

“通用疫苗不仅会更安全、更可靠、更便捷，它们的商业化还将终结大流行时代，”格兰维尔说。“我特别兴奋能与未来风险投资公司的史蒂夫·尤尔韦松合作，因为他有着基于颠覆性技术创建新行业的成功记录。

This financing positions us to deliver on the U.S. government's stated goal of a universal influenza vaccine within five years and to extend our platform to other high-impact diseases that needlessly weigh on our medical systems and our lives.'.

这笔资金使我们有能力实现美国政府提出的在五年内研发出通用流感疫苗的目标，并将我们的平台扩展到其他对我们的医疗系统和生活造成不必要负担的高影响力疾病上。

As part of the financing, Emilio Emini, PhD—former CEO of the Gates Medical Research Institute, Director of the Gates Foundation HIV and tuberculosis programs, and former SVP of Vaccine R&D at Pfizer and Merck—joins Centivax's Board of Directors. Dr. Emini has been a major contributor to the development of multiple vaccines, including Prevnar, where he was responsible for its development for both pediatric and adult prevention of pneumococcal disease..

作为融资的一部分，埃米利奥·埃米尼博士——盖茨医学研究所前首席执行官、盖茨基金会艾滋病和结核病项目的主任，以及辉瑞和默克疫苗研发前高级副总裁——加入了Centivax的董事会。埃米尼博士在多种疫苗的开发中做出了重要贡献，包括Prevnar，他在其中负责该疫苗在儿童和成人中预防肺炎球菌疾病的开发工作。

'I very much look forward to working with the Centivax team as a member of the company's Board,' said Dr. Emini, PhD. 'Centivax's approach to the design and development of a truly universal influenza vaccine is unique and creative. As such, the approach has considerable potential for successfully achieving a goal that has proven elusive to date.'.

“我非常期待作为公司董事会成员与Centivax团队合作，”Emini博士说道，“Centivax在设计和开发一种真正通用的流感疫苗方面的做法独特且富有创意。因此，这种方法有相当大的潜力成功实现迄今为止一直难以达到的目标。”

In addition to venture backing, Centivax has secured $24 million to date in competitive, non-dilutive awards—beginning with a $2 million 'Grand Challenge: End the Pandemic Threat' grant from the Bill & Melinda Gates Foundation and followed by awards from CEPI, the National Institutes of Health, the Military Infectious Diseases Research Program, the U.S.

除了风险投资支持外，Centivax迄今为止已获得了2400万美元的竞争性、非稀释性奖项——最初是比尔及梅琳达·盖茨基金会提供的200万美元“重大挑战：终结大流行威胁”拨款，随后还获得了流行病防范创新联盟（CEPI）、美国国立卫生研究院、美军传染病研究计划和美国其他机构的奖项。

Naval Medical Research Command, and others..

海军医学研究司令部，以及其他。。

'In today's financing climate, we are proud to have assembled an exceptional syndicate of investors and an exceptional team, both of which have an impressive track record of bringing breakthrough technologies to market,' said co-founder and Chief Business Officer Stephanie Wisner. 'This funding carries us through first-in-human studies—a value-inflection point that will catalyze the next phase of growth for Centivax and move the first universal flu vaccine one step closer to market.'.

“在当今的融资环境中，我们很自豪能够组建了一支卓越的投资者财团和一支卓越的团队，这两者都在将突破性技术推向市场方面有着令人印象深刻的记录，”联合创始人兼首席商务官斯蒂芬妮·威斯纳表示。“这笔资金将帮助我们完成首次人体研究——这是一个价值拐点，将会推动Centivax下一阶段的增长，并使首个通用流感疫苗更接近市场。”

About Centivax

关于Centivax

Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets. The lead clinical candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: How to Prevent an Outbreak, and other outlets—addresses a greater than $7 billion global flu market, with follow-on programs spanning a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom.

Centivax是一家通用免疫公司，利用其专有的计算免疫工程平台来开发能够提供针对整个多样化目标类别的通用保护的疫苗和疗法。其主打的流感临床候选产品——曾被《纽约客》、Netflix纪录片系列《大流行：如何预防疫情爆发》及其他媒体报道——针对的是一个超过70亿美元的全球流感市场，后续研发项目涵盖不断扩展的产品线，包括呼吸道合胞病毒/人类偏肺病毒（RSV/hMPV）、疱疹病毒、HIV、疟疾、肿瘤学以及一种通用抗蛇毒血清。

This growing portfolio underscores the technology's broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease.

这一不断增长的产品组合突显了该技术的广泛潜力，不仅能够防护包括病毒、细菌、原生动物、真菌、寄生虫和人为生物恐怖威胁在内的多种传染病，还能够通过减少这些病原体可能引发的长期并发症（如癌症、自身免疫疾病、心血管和神经退行性疾病）来延长健康寿命。

Centivax is headquartered in South San Francisco, California. Visit www.centivax.com and follow @Centivax on X..

Centivax 总部位于加利福尼亚州南旧金山。访问 www.centivax.com 并在 X 上关注 @Centivax。

Contact:

联系人：

Media Contact

媒体联系人

Stephanie Wisner, MBA

斯蒂芬妮·威斯纳，工商管理硕士

Chief Business Officer

首席商务官

stephanie@centivax.com | +1 415-712-0001

stephanie@centivax.com | +1 415-712-0001